iSpecimen Inc.

1.11
-0.07 (-5.93%)
At close: Mar 28, 2025, 3:59 PM
1.15
3.88%
After-hours: Mar 28, 2025, 06:49 PM EDT

Company Description

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide.

Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.

The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.

It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.

The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

iSpecimen Inc.
iSpecimen Inc. logo
Country United States
IPO Date Jun 17, 2021
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 53
CEO Robert Bradley Lim

Contact Details

Address:
450 Bedford Street
Lexington, Massachusetts
United States
Website https://ispecimen.com

Stock Details

Ticker Symbol ISPC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001558569
CUSIP Number 45032V108
ISIN Number US45032V1089
Employer ID 27-0480143
SIC Code 8731

Key Executives

Name Position
Robert Bradley Lim Chief Executive Officer, Treasurer, Secretary & Director
Yuying Liang Chief Financial Officer
Annette Arnold Vice President of Sales & Business Development
Carly Lejnieks Vice President of Marketing
Katharyn Field President
Leslie Hoyt Senior Vice President of Operations

Latest SEC Filings

Date Type Title
Mar 26, 2025 NT 10-K Filing
Mar 11, 2025 8-K Current Report
Feb 28, 2025 8-K/A [Amend] Current Report
Feb 24, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Jan 30, 2025 3 Filing
Jan 16, 2025 8-K Current Report
Dec 30, 2024 8-K Current Report
Dec 20, 2024 8-K Current Report
Dec 13, 2024 3 Filing